Cantargia (CANTA) Q4 2024 earnings summary

Executive summary

• Leadership transitioned to a new CEO with extensive pharma and biotech experience, aiming to accelerate value creation and pursue transactions for key assets.

• Focus remains on advancing two lead programs: nadunolimab (oncology) and CAN10 (autoimmune/inflammatory diseases), both showing promising clinical and biomarker results, with expanded CAN10 phase 1 study due to favorable safety data.

• Rights issue completed in Q4 2024, raising SEK 120 million before expenses to fund operations into 2025/2026.

• Key clinical milestones expected in H1 2025, including new results for both lead projects and the start of phase 2 studies.

Financial highlights

• Operating expenses for Q4 2024 reduced by 43% year-over-year; full-year operating expenses down 42% to SEK 168.6 million.

• R&D expenses for Q4 2024 were SEK 36.6 million, down 46% year-over-year; G&A expenses for Q4 were SEK 3.9 million.

• Q4 operating loss improved to SEK -40.7 million from SEK -71.1 million year-over-year; full-year operating loss SEK -168.6 million.

• Net cash outflow in Q4 was SEK 26 million; available funds at year-end reported as SEK 33 million, virtually SEK 140 million after rights issue proceeds in January.

Outlook and guidance

• Runway extends to end of 2025 or early 2026, excluding the start of new phase II studies for CAN10 or nadunolimab, which would require additional transactions.

• Multiple clinical and regulatory milestones expected in 2024–2025, including phase II study initiations and key data readouts.

• Ongoing efforts to secure additional financing or business development deals.